Akili, Inc.

Akili, Inc., trading under the ticker DNAA, is a digital medicine company that reached public markets through a SPAC merger in 2022, making it one of the more closely watched healthcare-sector de-SPAC stories of that cycle. The Boston-based company develops software-based therapeutics, most notably EndeavorRx, an FDA-authorized prescription digital treatment for pediatric ADHD. The May 2023 8-K filing, accession number 0001193125-23-135899, represents routine post-merger current reporting as the company operates as a fully public entity following the close of its business combination. Akili sits at the intersection of digital health and regulated therapeutics, a niche that drew significant SPAC capital during the 2020-2022 wave. For the full filing history, sponsor details, deal structure, and ongoing corporate disclosures for DNAA, sign up for complete data access at SpacDesk.